FibroBiologics (Direct Listing)

Note: This is NOT an IPO. This is a NASDAQ direct listing. The trade date is Jan. 31, 2024, according to the prospectus. Maxim Group is the financial  advisor. There is no underwriter. We are a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant […]

January 25, 2024 Read More

BBB Foods Inc.

We are pioneers and leaders of the grocery hard discount model in Mexico and one of the fastest-growing retailers in the country as measured by our sales and store growth rates. (Incorporated in the British Virgin Islands) The 3B name, which references “Bueno, Bonito y Barato” – a Mexican saying which translates to “Good, Nice […]

January 21, 2024 Read More

Kyverna Therapeutics

We are a Phase 2 clinical biopharmaceutical company (biotech) developing cell therapies for patients suffering from autoimmune diseases. Our initial focus is on lupus nephritis (LN) and systemic sclerosis (SSc). (Incorporated in Delaware) We are a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our goal is to […]

January 17, 2024 Read More

Rectitude Holdings, Ltd.

We are a Singapore-based holding company whose underlying business provides safety equipment, ranging from personal protective clothing, gloves and safety footwear, to portable fire extinguishers. rubber speed bumps and other  items. (Incorporated in the Cayman Islands) The company also supplies industrial hardware tools and electrical hardware for construction sites. Rectitude’s products are marketed to distributor […]

January 16, 2024 Read More

Palmer Square Capital BDC, Inc.

**Note: This is an IPO but it is NOT the type traditionally covered by IPOScoop. This is the IPO of a closed-end investment management company that has chosen to be regulated as a business development company (BDC). The IPO Profile here and the listing on the IPO Calendar are extended as a professional courtesy. IPOScoop […]

Read More

Alto Neuroscience, Inc.

  We are a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. (Incorporated in Delaware) Building on more than a decade of research by our founder, Dr. Amit Etkin, we aim to deeply understand brain function and match patients to the right medication more […]

January 12, 2024 Read More

Love & Health Ltd.

We are a newly organized blank check company. We intend to focus on businesses that have their primary operations in FinTech, financial services, business services, technology, consumer goods and other new economy industries. (Incorporated in the Cayman Islands) (Note: Love & Health Ltd. filed the S-1 for its SPAC IPO on Jan. 8, 2024, and […]

January 9, 2024 Read More

Zhengye Biotechnology Holding Limited

We are a holding company incorporated in the Cayman Islands. Our underlying business is a Chinese company that makes and distributes vaccines for livestock. (Incorporated in the Cayman Islands)  We, through the operating entity, focus on the research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. For nearly 20 years, […]

Read More

Auna S.A.

We operate hospitals and clinics in Spanish-speaking Latin America – specifically, in Mexico, Colombia and Peru. We also provide prepaid healthcare plans in Peru. We offer dental and vision plans in Mexico. (Incorporated in Luxembourg) As of Dec. 31, 2023, our network of facilities included 15 hospitals with 2,301 beds and 16 outpatient, prevention and wellness […]

Read More

ArriVent BioPharma, Inc.

We are a Phase 3 clinical biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. (Incorporated in Delaware) We seek to utilize our team’s deep drug development experience to maximize the potential of our lead development candidate, furmonertinib, and advance a pipeline […]

January 7, 2024 Read More
Page 24 of 283« First...10...2223242526...304050...Last »